Cytokine Therapy: Boosting Immunity Against Cancer

Introduction

The human immune system combats cancerous cells. However, tumors develop ways to evade this defense, allowing them to grow. Cytokine therapy is an emerging immunotherapy strategy that harnesses the immune system to fight cancer. This article explores how cytokines work, their use in treatment, and ongoing research to improve their effectiveness.

Cytokines: Immune System Messengers

Cytokines are small signaling molecules produced by immune cells. They act like a communication network, coordinating the immune response. Different cytokines have specific functions:

  • Stimulatory cytokines: These activate and expand immune effector cells, like cytotoxic T lymphocytes (CTLs), which directly kill cancer cells (e.g., interleukin-2 (IL-2), interferon-alpha (IFN-α)).
  • Modulatory cytokines: These influence the balance between pro-inflammatory and anti-inflammatory processes within the tumor microenvironment (TME) (e.g., interleukin-10 (IL-10), transforming growth factor-beta (TGF-β)).

Cellular and humoral immune responses induced by messenger RNA (mRNA) vaccine. mRNA delivered in an mRNA vaccine enters cells by endocytosis and, after release from the endosome, is translated into protein by ribosomes. Translated proteins can then activate the immune system primarily in two ways: i) proteins are degraded by the proteasome into peptides subsequently presented as antigens on the cell surface by major histocompatibility complex (MHC) class I molecules which bind to the T cell receptor (TCR) to activate CD8 + T cells to kill infected cells thorugh the secretion of perforin and granzyme; ii) proteins secreted extracellularly are engulfed by antigen-presenting cells (APCs) and degraded into peptides subsequently presented on the cell surface by MHC class II molecules for recognition by CD4 + T cells, which can activate both the cellular immune responses by secreting cytokines and the humoral immune responses by co-activating B cells. In addition, single-stranded RNA and double-stranded RNA delivered in mRNA vaccines bind to Toll-like receptor (TLR) in the endosome to activate the antiviral innate immune responses via the production of type-I interferon (IFN-I) which results in the induction of several IFN-1-stimulated genes involved in antiviral innate immunity, in a mechanism known as the self-adjuvant effect of a sequence-engineered mRNA.

Cytokines in Cancer Immunotherapy

Cytokine therapy aims to stimulate the immune system to recognize and destroy cancer cells. Treatment involves giving patients either natural or recombinant cytokines:

  • Natural cytokines: Extracted from immune cells or blood products.
  • Recombinant cytokines: Produced through genetic engineering for a consistent and large supply.

Clinical Applications

Cytokine therapy has shown effectiveness in treating specific cancers, including:

  • Melanoma: IL-2 therapy is approved for advanced melanoma, increasing tumor-infiltrating lymphocytes (TILs) and causing tumor shrinkage.
  • Renal cell carcinoma (RCC): Similar to melanoma, IL-2 therapy is used for RCC, promoting TIL expansion and potentially leading to long-lasting responses.
  • Hairy cell leukemia: IFN-α is a primary treatment for hairy cell leukemia, directly inhibiting cancer cell growth and proliferation.

Cytokines in Cancer Immunotherapy

Challenges and Future Directions

Despite its promise, cytokine therapy faces challenges:

  • Toxicity at high doses: High-dose therapy can cause severe side effects, requiring careful dose adjustment.
  • Short lifespan in the body: Cytokines degrade rapidly, necessitating frequent administration or development of sustained-release formulations.
  • Limited effectiveness in some cancers: Certain tumors resist cytokine therapy, highlighting the need for personalized treatment approaches.

Ongoing clinical trials cancer immunotherapy using IL-2 and modified IL-2.

Researchers are exploring ways to overcome these limitations:

  • Combination therapy: Combining cytokines with other immunotherapies may enhance anti-tumor responses and reduce side effects.
  • Targeted delivery systems: Encapsulating cytokines in nanoparticles or using antibody-drug conjugates can deliver them specifically to the tumor site, reducing side effects.
  • New cytokine targets: Studying the complex cytokine network within the TME may lead to new therapeutic targets with improved efficacy.

Conclusion

Cytokine therapy is a valuable tool in cancer treatment. By stimulating the immune system, cytokines can induce long-lasting anti-tumor effects. With ongoing research focused on overcoming limitations and optimizing delivery methods, cytokine therapy has immense potential to improve outcomes for various cancers.

Learn more in this video:



in News
Cytokine Therapy: Boosting Immunity Against Cancer
Gen store June 14, 2024
Tags
Our blogs
Sign in to leave a comment
Inflammation and Disease: A Key Contributor